Video from JFR 2022: Rémy-Jardin on photon-counting CT's promise

2022 10 07 23 30 0926 Remy Jardin Martine 400

PARIS - There is well-deserved excitement around photon-counting CT and the technology will have important clinical implications, Prof. Martine Rémy-Jardin said in an exclusive interview with at the JFR, the annual meeting of the French Society of Radiology.

"It's going to change many things," Rémy-Jardin said in an interview with correspondent Mélisande Rouger. The new technology "is opening the possibility to have new areas of development. We are in our first appreciation of what can be done. We're very excited."

Many thoracic patients are likely to benefit from photon-counting CT, according to Rémy-Jardin, who has been using the technique at her institution in Lille for just over a year. "We know that from the visual analysis of images right now there's a limit in the depiction of findings, and with this technique, we are improving our insights in different organs. It's going to change very much how we're going to approach these disorders," she said.

Regarding imaging of pulmonary embolism, one of her main areas of specialty, many people still need to be convinced of the clinical value of lung perfusion with CT. "It's available but it's probably underused right now, as it represents a very important complement to morphology. This analysis of lung microcirculation is a great area for nowadays," she said.

Rémy-Jardin also stressed how important lung perfusion is to assessing long-term effects of COVID-19, a topic she addressed in a JFR session later in the afternoon on Friday 7 October.

Prof. Martine Rémy-Jardin shares her thoughts on photon counting CT, pulmonary embolism, and lung perfusion.

Page 1 of 1240
Next Page